Xenogene vaccination in the therapy of cancer

Bibliography

• Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342(6165):1432-3
   PubMed Web of Science ®Google Scholar
• Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014;123(17):2625-35
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hodi FS, Weber JS, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann NY Acad Sci 2013;1291:1-13
   PubMed Web of Science ®Google Scholar
• Simeone E, Ascierto PA. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. J Immunotoxicol 2012;9(3):241-7
   PubMed Web of Science ®Google Scholar
• Page DB, Postow MA, Callahan MK, et al. Immune modulation in cancer with antibodies. Annu Rev Med 2014;65:185-202
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369(2):122-33
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 2014;257(1):56-71
   PubMed Web of Science ®Google Scholar
• Hershkovitz L, Schachter J, Treves AJ, Besser MJ. Focus on adoptive T cell transfer trials in melanoma. Clin Dev Immunol 2010;2010:260267
   PubMedGoogle Scholar
• Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013;3(4):388-98
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3(95):95ra73
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22
   PubMed Web of Science ®Google Scholar
• Jonsson B, Wilking N. Cancer vaccines and immunotherapeutics: challenges for pricing, reimbursement and market access. Hum Vaccin Immunother 2012;8(9):1360-3
   PubMed Web of Science ®Google Scholar
• Dawson NA, Roesch EE. Sipuleucel-T and immunotherapy in the treatment of prostate cancer. Expert Opin Biol Ther 2014;14(5):709-19
   PubMed Web of Science ®Google Scholar
• Coulie PG, Van Den Eynde BJ, Van Der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014;14(2):135-46
   PubMed Web of Science ®Google Scholar
• Guo C, Manjili MH, Subjeck JR, et al. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res 2013;119:421-75
   PubMed Web of Science ®Google Scholar
• Aurisicchio L, Ciliberto G. Genetic cancer vaccines: current status and perspectives. Expert Opin Biol Ther 2012;12(8):1043-58
   PubMed Web of Science ®Google Scholar
• Aurisicchio L, Mancini R, Ciliberto G. Cancer vaccination by electro-gene-transfer. Expert Rev Vaccines 2013;12(10):1127-37
   PubMed Web of Science ®Google Scholar
• Bagarazzi ML, Yan J, Morrow MP, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012;4(155):155ra138
   PubMed Web of Science ®Google Scholar
• Aurisicchio L, Fridman A, Bagchi A, et al. A novel minigene scaffold for therapeutic cancer vaccines. Oncoimmunology 2014;3:e27529
   Google Scholar
• Naftzger C, Takechi Y, Kohda H, et al. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA 1996;93(25):14809-14
   PubMed Web of Science ®Google Scholar
• Disis ML, Shiota FM, Cheever MA. Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for ’self’ tumour antigens. Immunology 1998;93(2):192-9
   PubMed Web of Science ®Google Scholar
• Jacob J, Radkevich O, Forni G, et al. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol 2006;240(2):96-106
   PubMed Web of Science ®Google Scholar
• Jacob JB, Quaglino E, Radkevich-Brown O, et al. Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity. Cancer Res 2010;70(1):119-28
   PubMed Web of Science ®Google Scholar
• Quaglino E, Riccardo F, Macagno M, et al. Chimeric DNA vaccines against ErbB2+ carcinomas: from mice to humans. Cancers (Basel) 2011;3(3):3225-41
   PubMedGoogle Scholar
• Quaglino E, Mastini C, Amici A, et al. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res 2010;70(7):2604-12
   PubMed Web of Science ®Google Scholar
• Quaglino E, Mastini C, Forni G, Cavallo F. ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. Curr Protoc Immunol 2008; Chapter 20:Unit 20.9.1-20.9.10. edited by John E. Coligan. et al
   PubMedGoogle Scholar
• Rolla S, Nicolo C, Malinarich S, et al. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 2006;177(11):7626-33
   PubMed Web of Science ®Google Scholar
• Piechocki MP, Ho YS, Pilon S, Wei WZ. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 2003;171(11):5787-94
   PubMed Web of Science ®Google Scholar
• Gallo P, Dharmapuri S, Nuzzo M, et al. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 2005;113(1):67-77
   PubMed Web of Science ®Google Scholar
• Pupa SM, Iezzi M, Di Carlo E, et al. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res 2005;65(3):1071-8
   PubMed Web of Science ®Google Scholar
• Tegerstedt K, Lindencrona JA, Curcio C, et al. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res 2005;65(13):5953-7
   PubMed Web of Science ®Google Scholar
• Triulzi C, Vertuani S, Curcio C, et al. Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors. Cancer Res 2010;70(19):7431-41
   PubMed Web of Science ®Google Scholar
• Rolla S, Ria F, Occhipinti S, et al. Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy. J Immunol 2010;184(11):6124-32
   PubMed Web of Science ®Google Scholar
• Gold JS, Ferrone CR, Guevara-Patino JA, et al. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 2003;170(10):5188-94
   PubMed Web of Science ®Google Scholar
• Holmgren L, Ambrosino E, Birot O, et al. A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci USA 2006;103(24):9208-13
   PubMed Web of Science ®Google Scholar
• Petrova G, Ferrante A, Gorski J. Cross-reactivity of T cells and its role in the immune system. Crit Rev Immunol 2012;32(4):349-72
   PubMed Web of Science ®Google Scholar
• Cole DK, Pumphrey NJ, Boulter JM, et al. Human TCR-binding affinity is governed by MHC class restriction. J Immunol 2007;178(9):5727-34
   PubMed Web of Science ®Google Scholar
• Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993;11:213-44
   PubMed Web of Science ®Google Scholar
• Hammer J, Bono E, Gallazzi F, et al. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med 1994;180(6):2353-8
   PubMed Web of Science ®Google Scholar
• Evavold BD, Sloan-Lancaster J, Wilson KJ, et al. Specific T cell recognition of minimally homologous peptides: evidence for multiple endogenous ligands. Immunity 1995;2(6):655-63
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Takeshita T, Pendleton CD, et al. The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T cell recognition. J Immunol 1993;150(2):331-41
   PubMed Web of Science ®Google Scholar
• Kersh GJ, Allen PM. Essential flexibility in the T-cell recognition of antigen. Nature 1996;380(6574):495-8
   PubMed Web of Science ®Google Scholar
• Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994;76(2):287-99
   PubMed Web of Science ®Google Scholar
• Pamer E, Cresswell P. Mechanisms of MHC class I – restricted antigen processing. Annu Rev Immunol 1998;16:323-58
   PubMed Web of Science ®Google Scholar
• Xu M, Kallinteris NL, Von Hofe E. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines. Vaccine 2012;30(18):2805-10
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Ottensmeier CH, Johnson P, et al. DNA vaccines to attack cancer. Proc Natl Acad Sci USA 2004;101(Suppl 2):14646-52
   PubMed Web of Science ®Google Scholar
• Lazoura E, Apostolopoulos V. Insights into peptide-based vaccine design for cancer immunotherapy. Curr Med Chem 2005;12(13):1481-94
   PubMed Web of Science ®Google Scholar
• Pinilla-Ibarz J, May RJ, Korontsvit T, et al. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia 2006;20(11):2025-33
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4(3):321-7
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Lenz HJ, Marshall J, et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res 2008;14(15):4843-9
   PubMed Web of Science ®Google Scholar
• Valmori D, Levy F, Miconnet I, et al. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J Immunol 2000;164(2):1125-31
   PubMed Web of Science ®Google Scholar
• Hoffmann TK, Loftus DJ, Nakano K, et al. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope. J Immunol 2002;168(3):1338-47
   PubMed Web of Science ®Google Scholar
• Vertuani S, Sette A, Sidney J, et al. Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues. J Immunol 2004;172(6):3501-8
   PubMed Web of Science ®Google Scholar
• Fridman A, Finnefrock AC, Peruzzi D, et al. An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platform. Oncoimmunology 2012;1(8):1258-70
   PubMed Web of Science ®Google Scholar
• Parmiani G, Castelli C, Dalerba P, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002;94(11):805-18
   PubMed Web of Science ®Google Scholar
• Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998;188(2):277-86
   PubMed Web of Science ®Google Scholar
• Bowne WB, Srinivasan R, Wolchok JD, et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999;190(11):1717-22
   PubMed Web of Science ®Google Scholar
• Kianizad K, Marshall LA, Grinshtein N, et al. Elevated frequencies of self-reactive CD8+ T cells following immunization with a xenoantigen are due to the presence of a heteroclitic CD4+ T-cell helper epitope. Cancer Res 2007;67(13):6459-67
   PubMed Web of Science ®Google Scholar
• Wong AL, Lee SC. Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer. Int J Breast Cancer 2012;2012:415170
   PubMedGoogle Scholar
• Marchini C, Kalogris C, Garulli C, et al. Tailoring DNA Vaccines: designing Strategies Against HER2-Positive Cancers. Front Oncol 2013;3:122
   Google Scholar
• De Giovanni C, Nicoletti G, Quaglino E, et al. Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. Breast Cancer Res 2014;16(1):R10
   PubMed Web of Science ®Google Scholar
• Finkle D, Quan ZR, Asghari V, et al. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res 2004;10(7):2499-511
   PubMed Web of Science ®Google Scholar
• Iezzi M, Quaglino E, Amici A, et al. DNA vaccination against oncoantigens: a promise. Oncoimmunology 2012;1(3):316-25
   PubMed Web of Science ®Google Scholar
• Occhipinti S, Sponton L, Rolla S, et al. Chimeric rat/human HER2 efficiently circumvents HER2 tolerance in cancer patients. Clin Cancer Res 2014. [ Epub ahead of print]
   Google Scholar
• Uva P, Aurisicchio L, Watters J, et al. Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics 2009;10:135
   PubMed Web of Science ®Google Scholar
• Bergman PJ, Camps-Palau MA, Mcknight JA, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006;24(21):4582-5
   PubMed Web of Science ®Google Scholar
• Bergman PJ, Mcknight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003;9(4):1284-90
   PubMed Web of Science ®Google Scholar
• Manley CA, Leibman NF, Wolchok JD, et al. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. J Vet Intern Med 2011;25(1):94-9
   PubMed Web of Science ®Google Scholar
• Grosenbaugh DA, Leard AT, Bergman PJ, et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 2011;72(12):1631-8
   PubMed Web of Science ®Google Scholar
• Liao JC, Gregor P, Wolchok JD, et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 2006;6:8
   PubMedGoogle Scholar
• Michaeli Y, Denkberg G, Sinik K, et al. Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies. J Immunol 2009;182(10):6328-41
   PubMed Web of Science ®Google Scholar
• Alexander AN, Huelsmeyer MK, Mitzey A, et al. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol Immunother 2006;55(4):433-42
   PubMed Web of Science ®Google Scholar
• Riccardo F, Iussich S, Maniscalco L, et al. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clin Cancer Res 2014; In press
   PubMed Web of Science ®Google Scholar
• Price MA, Colvin Wanshura LE, Yang J, et al. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res 2011;24(6):1148-57
   PubMed Web of Science ®Google Scholar
• Campoli M, Ferrone S, Wang X. Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv Cancer Res 2010;109:73-121
   PubMed Web of Science ®Google Scholar
• Mayayo SL, Prestigio S, Maniscalco L, et al. Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma. Vet J 2011;190(2):e26-30
   Google Scholar
• Kamstock D, Elmslie R, Thamm D, Dow S. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol Immunother 2007;56(8):1299-309
   PubMed Web of Science ®Google Scholar
• Yu WY, Chuang TF, Guichard C, et al. Chicken HSP70 DNA vaccine inhibits tumor growth in a canine cancer model. Vaccine 2011;29(18):3489-500
   PubMed Web of Science ®Google Scholar
• Fong L, Brockstedt D, Benike C, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001;167(12):7150-6
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Yuan J, Houghton AN, et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther 2007;15(11):2044-50
   PubMed Web of Science ®Google Scholar
• Yuan J, Ku GY, Adamow M, et al. Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. J Immunother Cancer 2013;1:20
   PubMedGoogle Scholar
• Yuan J, Ku GY, Gallardo HF, et al. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun 2009;9:5
   PubMedGoogle Scholar
• Ginsberg BA, Gallardo HF, Rasalan TS, et al. Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clin Cancer Res 2010;16(15):4057-65
   PubMed Web of Science ®Google Scholar
• Eriksson F, Totterman T, Maltais AK, et al. DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer. Vaccine 2013;31(37):3843-8
   PubMed Web of Science ®Google Scholar
• Weber LW, Bowne WB, Wolchok JD, et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998;102(6):1258-64
   PubMed Web of Science ®Google Scholar
• Steitz J, Bruck J, Steinbrink K, et al. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int J Cancer 2000;86(1):89-94
   PubMed Web of Science ®Google Scholar
• Tormo D, Ferrer A, Bosch P, et al. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res 2006;66(10):5427-35
   PubMed Web of Science ®Google Scholar
• Hawkins WG, Gold JS, Dyall R, et al. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 2000;128(2):273-80
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Xanthopoulos KG. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18. DNA Cell Biol 2005;24(5):317-24
   PubMed Web of Science ®Google Scholar
• Su JM, Wei YQ, Tian L, et al. Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res 2003;63(3):600-7
   PubMed Web of Science ®Google Scholar
• Lou YY, Wei YQ, Yang L, et al. Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin beta3. Immunol Invest 2002;31(1):51-69
   PubMed Web of Science ®Google Scholar
• Liu JY, Wei YQ, Yang L, et al. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 2003;102(5):1815-23
   PubMed Web of Science ®Google Scholar
• Wei Y, Sun Y, Song C, et al. Enhancement of DNA vaccine efficacy by targeting the xenogeneic human chorionic gonadotropin, survivin and vascular endothelial growth factor receptor 2 combined tumor antigen to the major histocompatibility complex class II pathway. J Gene Med 2012;14(5):353-62
   PubMed Web of Science ®Google Scholar
• He QM, Wei YQ, Tian L, et al. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem 2003;278(24):21831-6
   PubMed Web of Science ®Google Scholar
• Sioud M, Sorensen D. Generation of an effective anti-tumor immunity after immunization with xenogeneic antigens. Eur J Immunol 2003;33(1):38-45
   PubMed Web of Science ®Google Scholar
• Lu Y, Wei YQ, Tian L, et al. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. J Immunol 2003;170(6):3162-70
   PubMed Web of Science ®Google Scholar
• Lai MD, Yen MC, Lin CM, et al. The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model. Genet Vaccines Ther 2009;7:2
   PubMedGoogle Scholar
• Tan GH, Wei YQ, Tian L, et al. Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen. Eur J Immunol 2004;34(7):2012-21
   PubMed Web of Science ®Google Scholar
• Jiao JG, Li YN, Wang H, et al. A plasmid DNA vaccine encoding the extracellular domain of porcine endoglin induces anti-tumour immune response against self-endoglin-related angiogenesis in two liver cancer models. Dig Liver Dis 2006;38(8):578-87
   PubMedGoogle Scholar
• Goldberg SM, Bartido SM, Gardner JP, et al. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clin Cancer Res 2005;11(22):8114-21
   PubMed Web of Science ®Google Scholar
• Palomba ML, Roberts WK, Dao T, et al. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin Cancer Res 2005;11(1):370-9
   PubMed Web of Science ®Google Scholar
• Gregor PD, Wolchok JD, Turaga V, et al. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer 2005;116(3):415-21
   PubMed Web of Science ®Google Scholar
• Mincheff M, Zoubak S, Makogonenko Y. Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals. Cancer Gene Ther 2006;13(4):436-44
   PubMed Web of Science ®Google Scholar
• Charalambous A, Oks M, Nchinda G, et al. Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin. J Immunol 2006;177(12):8410-21
   PubMed Web of Science ®Google Scholar
• Ciesielski MJ, Apfel L, Barone TA, et al. Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas. Cancer Immunol Immunother 2006;55(12):1491-503
   PubMed Web of Science ®Google Scholar
• Luo Y, Wen YJ, Ding ZY, et al. Immunotherapy of tumors with protein vaccine based on chicken homologous Tie-2. Clin Cancer Res 2006;12(6):1813-19
   PubMed Web of Science ®Google Scholar
• Harrop R, Ryan MG, Myers KA, et al. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer Immunol Immunother 2006;55(9):1081-90
   PubMed Web of Science ®Google Scholar
• Zhang W, Liu J, Wu Y, et al. Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous alpha fetoprotein in mice. Biochem Biophys Res Commun 2008;376(1):10-14
   PubMed Web of Science ®Google Scholar
• Huebener N, Fest S, Hilt K, et al. Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma. Mol Cancer Ther 2009;8(8):2392-401
   PubMed Web of Science ®Google Scholar
• Xie J, Xiong L, Tao X, et al. Antitumor effects of murine bone marrow-derived dendritic cells infected with xenogeneic livin alpha recombinant adenoviral vectors against Lewis lung carcinoma. Lung Cancer 2010;68(3):338-45
   PubMed Web of Science ®Google Scholar
• Soong RS, Trieu J, Lee SY, et al. Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53. PLoS One 2013;8(2):e56912
   PubMed Web of Science ®Google Scholar